Gilead Sciences
GILD
1,678 hedge funds and large institutions have $71.8B invested in Gilead Sciences in 2024 Q2 according to their latest regulatory filings, with 130 funds opening new positions, 649 increasing their positions, 687 reducing their positions, and 150 closing their positions.
40% more call options, than puts
Call options by funds: $1.02B | Put options by funds: $726M
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
0.12% less ownership
Funds ownership: 83.43% → 83.31% (-0.12%)
6% less repeat investments, than reductions
Existing positions increased: 649 | Existing positions reduced: 687
2% less funds holding
Funds holding: 1,721 → 1,678 (-43)
6% less capital invested
Capital invested by funds: $76.1B → $71.8B (-$4.3B)
13% less first-time investments, than exits
New positions opened: 130 | Existing positions closed: 150
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$266M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$158M |
| 3 |
D.E. Shaw & Co
New York
|
+$147M |
| 4 |
Millennium Management
New York
|
+$132M |
| 5 |
Swedbank
Stockholm,
Sweden
|
+$124M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$550M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$337M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$239M |
| 4 |
Barclays
London,
United Kingdom
|
-$144M |
| 5 |
BlackRock
New York
|
-$127M |
GILD Hedge Fund Activity: Q2 2024 in Review
1,678 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2024, worth a combined $71.8B — down 5.6% from $76.1B a quarter earlier.
Sellers outnumbered buyers: 150 funds closed out of GILD and 130 opened new positions — a net loss of 20 holders — while 687 trimmed existing stakes and 649 added.
The largest buyer was Goldman Sachs, adding an estimated $266M. The largest seller was Capital World Investors, cutting an estimated $550M.
- 1,678 institutional investors held Gilead Sciences (GILD) as of Q2 2024, down from 1,721 in Q1 2024.
- Funds reported $71.8B of Gilead Sciences stock for Q2 2024, down 5.6% quarter-over-quarter.
- 130 funds opened new Gilead Sciences positions in Q2 2024 and 150 closed out, a net change of -20 holders.
- The largest Gilead Sciences buyer in Q2 2024 was Goldman Sachs, an estimated $266M added.
- The largest Gilead Sciences seller in Q2 2024 was Capital World Investors, an estimated $550M sold.
Based on aggregated 13F filings for Q2 2024.